@UHhospitals @AASLDNews Dr. Anthony Post covers the topic of #HBV at the #AASLD #LIVER15 update https://t.co/Qj6ZNP6kAe

It's been real San Francisco. Already looking forward to #liver16 in Boston 11/11-15, 2016
#Liver15 #liverleader

Poster 2246: solithromycin pre-clinical data in STAM NASH mouse model #Liver15 #LiverLeader https://t.co/OnQrzksnXP

My take on treating acute #HCV with DAAs in light of data. Don't do it and wait 6 months then reassess #liver15 #LiverLeader

Dr. Terrault @UCSFTransplant delivers the annual tour de force that is the hepatitis debrief at #liver15 #LiverLeader

Five largest donors to @AASLDFoundation are @abbvie @GileadSciences @SalixPharma and Intercept #wecandomore #liver15 #LiverLeader

@AASLDFoundation outlines goals and achievements. 219% return on investment for donations in NIH research awards #wecandomore #liver15

Dr. Rockstroh: high SVR24 in GT1-4 #HCV #HIV. Q&A revolving around reinfection rates which may be as high as 25% at 12 wks #liver15

Issues with mother to child transmission study include HBV DNA cutoff and most who did not suppress virus still had no transmission #liver15

#tenofovir therapy in third trimester for moms w HBV DNA levels>200,000 IU/ml reduced mother to child transmission #Liver15

77% reduction in HCC incidence in #HBV high risk pts on antiviral rx even w/o cirrhosis. Rx beneficial even with HBV DNA PCR<1000 #Liver15

As a reminder ALLY-3+ study longest arm was 16 wks and showed 89% SVR12 with 12 wks #sofosbuvir #daclatasvir and ribavirin #liver15

Dr. Hezode: French compassionate use data for #sofosbuvir #daclatasvir in #HCV GT3 support 24 wks without RBV in cirrhosis #liver15

Last day of #liver15 dominated by #HCV treatment because this topic hasn't received enough attention (insert sarcasm here)

With #sofosbuvir #velpatasvir then ABT-493/530 data emerging, are we ushering era of #HCV genotype blind therapy? May be legacy of #liver15

#elafibranor data reassuring as cardiovascular liability is issue with NASH drug development and drug moving to ph3 at 120 mg dose #Liver15

Dr. Harrison: #Elafibranor at 120 mg dose lowers triglycerides, LDL, apoB & C3, Increases HDL vs placebo across disease spectrum #Liver15

Dr. Abdelmalek @Duke_GastroHep metabolomic profile shows alteration in bile acid,lipid & aa metabolism in NASH stage 3/4 fibrosis #Liver15

Dr. Africa: children with Zone 1 steatosis more likely to have advanced fibrosis, less likely to have steatohepatitis #Liver15 #LiverLeader

Dr. Hagstrom: diagnosis of severe liver disease occurred on average 14 years after diagnosis of diabetes. #Liver15 #LiverLeader

Dr. Hagstrom: 39y f/u of large Swedish conscript cohort shows BMI>25 in teens strongly assoc. w severe liver dz later #Liver15 #LiverLeader

Dr. Kleiner: NAS score v 2.0 coming. Unclear if yields more inter-observer variability. Do we still need steatosis? #Liver15 #LiverLeader

Dr. Kleiner: ballooning now classified as classical or none, severe or non, 0-4. New balloon score>2=NASH #Liver15 #LiverLeader #fattyliver

Late breaker: ELAD on life support, #sofosbuvir #velpatasvir pangenotypic cure for (almost) all. #emricasan promising #Liver15 #liverleader

Dr. Garcia-Tsao: 28d PO #emricasan reduces severe portal HTN in small group of compensated cirrhotics. ALT lower. #Liver15 #LiverLeader

Major issue with #HCV denial data: excluded patients ? more likely to be Medicaid recipients so could be even WORSE #Liver15 #liverleader

Dr. Lo Re: 16% denied #HCV treatment with 46% among Medicaid recipients mostly for "lack of medical necessity" #liverleader #Liver15

In ALLY-3+ extension to 16 wks didn't increase SVR12 in cirrhotics leading to question about whether 24 wks might #Liver15 #LiverLeader

Dr. Leroy: ALLY-3+ #daclatasvir #sofosbuvir+RBV for 12 or 16 wks gets 90% SVR12 overall and 86% in cirrhotic HCV GT3 #Liver15 #LiverLeader

Dr. Feld: in 2 patients who were not cured Y93H was detected at failure. Still role for #harvoni as 8 week data better #LiverLeader #liver15